-
1.发明申请公开(公告)号：US20200277252A1
公开(公告)日：2020-09-03
申请号：US16753035
申请日：2018-10-04
Applicant: Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou , MERCK SHARP & DOHME CORP.
Inventor： Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou
IPC: C07C237/42 , C07D241/24 , C07D213/82 , C07D233/90 , C07D263/34 , C07D231/14 , C07D277/56 , C07D239/28 , C07D213/75 , C07D309/14 , C07D237/20 , C07D307/14 , C07D205/04 , C07D285/06 , C07D487/04
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
2.发明申请公开(公告)号：US20190185486A1
公开(公告)日：2019-06-20
申请号：US16326043
申请日：2017-08-14
Applicant: Wensheng Yu , Joseph A. Kozlowski , Ling Tong , Craig A. Cobum , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang
Inventor： Wensheng Yu , Joseph A. Kozlowski , Ling Tong , Craig A. Cobum , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang
IPC: C07D498/04 , A61K31/5365 , A61K31/496 , A61K45/06 , A61P31/14
Abstract: The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
-
公开(公告)号：US20170362242A1
公开(公告)日：2017-12-21
申请号：US15538902
申请日：2015-12-17
Applicant: JIAN LIU , JOSEPH A. KOZLOWSKI , ABDUL-BASIT ALHASSAN , SOBHANA BABU BOGA , XIAOLEI GAO , DEODIAL GUY GUIADEEN , JYHSHING WANG , WENSHENG YU , JIAQIANG CAI , SHILAN LIU , DAHAI WANG , HAO WU , CHUNDAO YANG
Inventor： JIAN LIU , JOSEPH A. KOZLOWSKI , ABDUL-BASIT ALHASSAN , SOBHANA BABU BOGA , XIAOLEI GAO , DEODIAL GUY GUIADEEN , JYHSHING WANG , WENSHENG YU , JIAQIANG CAI , SHILAN LIU , DAHAI WANG , HAO WU , CHUNDAO YANG
IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , C07D519/00
CPC classification number: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06 , A61P37/02 , C07D519/00
Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
-
公开(公告)号：US20170217940A1
公开(公告)日：2017-08-03
申请号：US15104584
申请日：2014-12-15
Applicant: Joseph KOZLOWSKI , Craig COBURN , Wensheng YU , Bin HU , Bin ZHONG , Jinglai HAO , Dahai WANG , Tao JI , MERCL SHARP & DOHME CORP.
Inventor： Joseph Kozlowski , Craig Coburn , Wensheng Yu , Ling Tong , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang , Tao Ji
IPC: C07D405/14 , A61K31/4178 , A61K31/7072 , A61K45/06 , A61K31/4985
CPC classification number: C07D405/14 , A61K31/4155 , A61K31/4178 , A61K31/4985 , A61K31/7072 , A61K45/06 , C07D493/04 , A61K2300/00
Abstract: The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A′, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.
-
公开(公告)号：US08541572B2
公开(公告)日：2013-09-24
申请号：US13127952
申请日：2009-11-09
Applicant: Joseph A. Kozlowski , Wensheng Yu , Michael K. C. Wong , Seong Heon Kim , Ling Tong , Brian J. Lavey , Bandarpalle B. Shankar , De-Yi Yang , Robert Feltz , Aneta Maria Kosinski , Guowei Zhou , Razia K. Rizvi , Chaoyang Dai , Luke Fire , Vinay Girijavallabhan , Dansu Li , Janeta Popovici-Muller , Judson E. Richard , Kristin E. Rosner , M. Arshad Siddiqui , Liping Yang
Inventor： Joseph A. Kozlowski , Wensheng Yu , Michael K. C. Wong , Seong Heon Kim , Ling Tong , Brian J. Lavey , Bandarpalle B. Shankar , De-Yi Yang , Robert Feltz , Aneta Maria Kosinski , Guowei Zhou , Razia K. Rizvi , Chaoyang Dai , Luke Fire , Vinay Girijavallabhan , Dansu Li , Janeta Popovici-Muller , Judson E. Richard , Kristin E. Rosner , M. Arshad Siddiqui , Liping Yang
IPC: C07D295/03 , C07D241/20 , C07D211/30 , C07D213/46 , C07D403/06 , C07D203/16
CPC classification number: C07D403/14
Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof.
Abstract translation: 本发明涉及式（I）的化合物：（化学式应该插在这里，它以纸的形式出现）（I）或其药学上可接受的盐，溶剂合物或异构体，其可用于治疗 由MMP，ADAM，TACE，聚蛋白聚糖蛋白聚糖酶，TNF-或其组合介导的疾病或病症。
-
Patent Agency Ranking
公开(公告)号：US08361959B2
公开(公告)日：2013-01-29
申请号：US13121725
申请日：2009-09-30
Applicant: Andrew Stamford , Michael W. Miller , Duane Eugene DeMong , William J. Greenlee , Joseph A. Kozlowski , Brian J. Lavey , Michael K. C. Wong , Wensheng Yu , Xing Dai , De-Yi Yang , Guowei Zhou
Inventor： Andrew Stamford , Michael W. Miller , Duane Eugene DeMong , William J. Greenlee , Joseph A. Kozlowski , Brian J. Lavey , Michael K. C. Wong , Wensheng Yu , Xing Dai , De-Yi Yang , Guowei Zhou
IPC: A61F7/10 , A61K31/4184 , C07D235/02
CPC classification number: C07D235/02 , A61K31/4184 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/12 , C07D491/10 , A61K2300/00
Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
Abstract translation: 本发明涉及以下通式的化合物：（I）其中环A，环B，R 1，R 3，Z，L 1和L 2彼此独立地并且如本文所定义，包含该化合物的组合物，和 涉及使用该化合物作为胰高血糖素受体拮抗剂并用于治疗或预防2型糖尿病及与之有关的病症的方法。
-
公开(公告)号：US20110288077A1
公开(公告)日：2011-11-24
申请号：US13120730
申请日：2009-09-22
Applicant: Michael K.C. Wong , Wensheng Yu , Ling Tong , Brian J. Lavey , Bandarpalle B. Shankar , Joseph A. Kozlowski , Seong Heon Kim , Guowei Zhou , De-Yi Yang , Razia K. Rizvi , Lei Chen , Aneta Maria Kosinski , Kristen E. Rosner , Luke Fire , Judson E. Richard , Dansu Li
Inventor： Michael K.C. Wong , Wensheng Yu , Ling Tong , Brian J. Lavey , Bandarpalle B. Shankar , Joseph A. Kozlowski , Seong Heon Kim , Guowei Zhou , De-Yi Yang , Razia K. Rizvi , Lei Chen , Aneta Maria Kosinski , Kristen E. Rosner , Luke Fire , Judson E. Richard , Dansu Li
IPC: A61K31/4178 , C07D405/14 , C07D401/14 , C07D491/048 , A61K31/517 , A61K31/4355 , A61K31/4439 , A61K31/496 , A61K31/551 , A61P19/02 , A61P1/02 , A61P35/04 , A61P27/06 , A61P1/00 , A61P17/06 , A61P9/00 , A61P31/00 , A61P31/18 , C07D403/06
CPC classification number: C07D405/14 , C07D403/06 , C07D403/14 , C07D491/048
Abstract: This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α combinations thereof.
Abstract translation: 本发明涉及如本文定义的式（I） - （IX）：或其药学上可接受的盐，溶剂合物或酯的化合物，其可用于治疗由MMP，ADAM，TACE介导的疾病或病症 ，聚集蛋白聚糖酶，TNF-α组合。
-
8.发明申请公开(公告)号：US20110286969A1
公开(公告)日：2011-11-24
申请号：US13139131
申请日：2009-12-10
Applicant: Malcolm MacCoss , F. George Njoroge , Frank Bennett , Srikanth Venkatraman , Joseph A. Kozlowski , Wensheng Yu , Paul E. McNamara , Pernilla R. Royster
Inventor： Malcolm MacCoss , F. George Njoroge , Frank Bennett , Srikanth Venkatraman , Joseph A. Kozlowski , Wensheng Yu , Paul E. McNamara , Pernilla R. Royster
CPC classification number: A61K31/403 , A61K31/7056 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/64 , C07K5/06052 , A61K2300/00
Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as wet! as methods of using them to treat disorders associated with the HCV protease An illustrative inventsve compound is shown below: Formula (I).
Abstract translation: 本发明公开了具有HCV蛋白酶抑制活性的新化合物以及制备这些化合物的方法。在另一个实施方案中，本发明公开了包含湿润的化合物的药物组合物。 作为使用它们来治疗与HCV蛋白相关的病症的方法本发明的说明性化合物如下所示：式（I）。
-
9.发明申请FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权熔融的三聚硅氧烷化合物及其用于治疗病毒性疾病的方法公开(公告)号：US20110223134A1
公开(公告)日：2011-09-15
申请号：US13041082
申请日：2011-03-04
Applicant: Anilkumar Gopinadhan Nair , Kerry M. Keertikar , Seong Heon Kim , Joseph A. Kozlowski , Stuart Rosenblum , Oleg B. Selyutin , Michael Wong , Wensheng Yu , Qingbei Zeng
Inventor： Anilkumar Gopinadhan Nair , Kerry M. Keertikar , Seong Heon Kim , Joseph A. Kozlowski , Stuart Rosenblum , Oleg B. Selyutin , Michael Wong , Wensheng Yu , Qingbei Zeng
IPC: A61K38/21 , C07F7/02 , A61P31/12 , A61K31/695 , A61K31/7056
CPC classification number: C07F7/0816
Abstract: The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, M1, X1 and X2 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Silyl Compound, and methods of using the Fused Tricyclic Silyl Compounds for treating or preventing HCV infection in a patient.
Abstract translation: 本发明涉及式（I）的新型稠合三环甲硅烷基化合物及其药学上可接受的盐，其中A，B，C，D，M1，X1和X2如本文所定义。 本发明还涉及包含至少一种熔融三环甲硅烷基化合物的组合物，以及使用融合的三环甲硅烷基化合物治疗或预防患者HCV感染的方法。
-
公开(公告)号：US20090170875A1
公开(公告)日：2009-07-02
申请号：US12338425
申请日：2008-12-18
Applicant: Wensheng Yu , Ling Tong , Lei Chen , Joseph A. Kozlowski , Brian J. Lavey , Neng-Yang Shih , Vincent S. Madison , Guowei Zhou , Peter Orth , Zhuyan Guo , Michael K.C. Wong , De-Yi Yang , Seong Heon Kim , Bandarpalle B. Shankar , M. Arshad Siddiqui , Kristin E. Rosner , Chaoyang Dai , Umar Faruk Mansoor , Janeta Popovici-Muller , Vinay M. Girijavallabhan , Dansu Li
Inventor： Wensheng Yu , Ling Tong , Lei Chen , Joseph A. Kozlowski , Brian J. Lavey , Neng-Yang Shih , Vincent S. Madison , Guowei Zhou , Peter Orth , Zhuyan Guo , Michael K.C. Wong , De-Yi Yang , Seong Heon Kim , Bandarpalle B. Shankar , M. Arshad Siddiqui , Kristin E. Rosner , Chaoyang Dai , Umar Faruk Mansoor , Janeta Popovici-Muller , Vinay M. Girijavallabhan , Dansu Li
IPC: A61K31/497 , C07D403/06 , A61K31/4166 , A61K31/4709 , C07D403/14 , C07D401/14 , C07D417/14 , A61K31/427
CPC classification number: C07D403/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D473/34 , C07D487/04 , C07D491/04 , C07D495/04
Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
-
-
-
-
-
-
-
-
-
Search Results
67
records
(took 0.052 seconds)
